A research team has begun to unravel the role of RNA epigenetics and chromatin structure in the regulation of 5-azacytidine, a DNA hypomethylating agent in certain leukemias. The results could lead to novel strategies and biomarkers that could reduce the risk of drug resistance.
A new computational method allows scientists to identify rare gene mutations in cancer cells with greater accuracy and sensitivity than currently available approaches. The technique is called Lancet and represents a major advance in the identification of tumor cell mutations, a process known as somatic variant calling.
The population of bacteria in the pancreas increases more than a thousand fold in patients with pancreatic cancer, and becomes dominated by species that prevent the immune system from attacking tumor cells.
The efficacy of target specific therapies in lymphoma is limited to subgroups of patients. Scientists have identified a mechanism that confers resistance against a common therapy for lymphoma. They propose an alternative treatment that targets lymphoma signaling at its root, and show that it can be effective in a broader group of patients.
A newly designed three-part molecule could be the one answer patients with a certain form of breast cancer are looking for, scientists report. This chimera has the ability to simultaneously decrease the expression of three growth factors that are over-expressed in some cancers.